News

The agreements enable global travelers covered by HTH’s international health insurance programs to arrange convenient appointments for diagnostic and treatment services and to have the clinics bill HTH

In December 2007, GSK and Galapagos initiated a program to discover and develop novel anti-infective drug candidates for GSK’s Infectious Diseases Centre of Excellence in Drug Discovery (ID

deCODEme Cardio detects genetic risk factors for heart attack, stroke and atrial fibrillation, peripheral artery disease (PAD) and several other conditions. deCODEme Cancer measures genetic risk factors for

RiaSTAP is not indicated to treat dysfibrinogenemia. Approval was based on a pivotal Phase II prospective, open-label pharmacokinetic (PK) and safety study using maximum clot firmness (MCF) as

“The potential applications of magnetic sensor technology for future medical devices are nothing short of profound,” said Steven Van Fleet, president of (MASTInc). “Imagine a wristwatch-sized device that

These funds, which bear no interest, become repayable on the commercialization of C-Cure. The new funds, which have come from a range of new and existing investors, will

Before joining KineMatik, Mr Jarjour was vice president of global marketing at Organon. Previously, Mr Jarjour held key positions at top tier pharmaceutical organizations including Bristol-Myers Squibb, Pharmacia,

This initial safety study involves single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study are assessed for adverse side

This appointment, which represents a new position on the board, brings the total number of company directors to nine, with six serving independently. Current chairman Gregory Pusey is